Loss of PI3 kinase association improves the sensitivity of secondary mutation of KIT to Imatinib

被引：0
|
作者：
Guangrong Zhu
Jun Shi
Shaoting Zhang
Yue Guo
Ling Huang
Hui Zhao
Yideng Jiang
Jianmin Sun
机构：
[1] Ningxia Medical University,School of Basic Medical Sciences
[2] The Chinese University of Hong Kong,Key Laboratory for Regenerative Medicine, Ministry of Education, School of Biomedical Sciences, Faculty of Medicine
[3] Chinese Academy of Sciences-The Chinese University of Hong Kong Joint Laboratory of Bioresources and Molecular Research of Common Diseases,Kunming Institute of Zoology
[4] NHC Key Laboratory of Metabolic Cardiovascular Diseases Research (Ningxia Medical University),Division of Translational Cancer Research, Lund Stem Cell Center, Department of Laboratory Medicine
[5] Ningxia Key Laboratory of Vascular Injury and Repair Research,undefined
[6] Lund University,undefined
来源：
Cell & Bioscience | / 10卷
关键词：
KIT; GISTs; PI3 kinase; Imatinib; Drug resistance;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] PI3 kinase inhibition improves vascular malformations in mouse models of hereditary haemorrhagic telangiectasia
    Ola, Roxana
    Dubrac, Alexandre
    Han, Jinah
    Zhang, Feng
    Fang, Jennifer S.
    Larrivee, Bruno
    Lee, Monica
    Urarte, Ana A.
    Kraehling, Jan R.
    Genet, Gael
    Hirschi, Karen K.
    Sessa, William C.
    Canals, Francesc V.
    Graupera, Mariona
    Yan, Minhong
    Young, Lawrence H.
    Oh, Paul S.
    Eichmann, Anne
    NATURE COMMUNICATIONS, 2016, 7
  • [22] An open label trial of nemiralisib, an inhaled PI3 kinase delta inhibitor for the treatment of Activated PI3 kinase Delta Syndrome
    Begg, Malcolm
    Amour, Augustin
    Jarvis, Emily
    Tang, Teresa
    Franco, Sara Santos
    Want, Andrew
    Beerahee, Misba
    Fernando, Disala
    Karkera, Yakshitha
    Sander, Clare
    Southworth, Thomas
    Singh, Dave
    Clark, Jonathan
    Nejentsev, Sergey
    Okkenhaug, Klaus
    Condliffe, Alison
    Chandra, Anita
    Cahn, Anthony
    Hall, Edward Banham
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2023, 79
  • [23] The PI3 Kinase Signaling Pathway in Prostate Cancer
    Elfiky, Aymen A.
    Jiang, Zhenyang
    CURRENT CANCER DRUG TARGETS, 2013, 13 (02) : 157 - 164
  • [24] Assessment of PI3 kinase as a druggable target in melanoma
    Aziz, S. A.
    Pick-Golan, E.
    McCarthy, M. M.
    Flaherty, K. T.
    Camp, R. L.
    Rimm, D. L.
    Kluger, H. M.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [25] Regulation of cardiac substrate metabolism by PI3 kinase
    Mazumder, PK
    Graveleau, C
    Tuttle, MJ
    Betuing, S
    Belke, DD
    Shioi, T
    Izumo, S
    Abel, ED
    CIRCULATION, 2002, 106 (19) : 157 - 157
  • [26] Isoform specific inhibitors of PI3 kinase in glioma
    Fan, Qi-Wen
    Weiss, William A.
    CELL CYCLE, 2006, 5 (20) : 2301 - 2305
  • [27] A PI3 Kinase Inhibitor Found to Activate Bestrophin 3
    Qu, Zhiqiang
    Han, Xiaohua
    Cui, Yuanyuan
    Li, Chunlin
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 2010, 55 (01) : 110 - 115
  • [28] PI3 Kinase Pathway Mutations in Human Cancers
    Gray, Joe W.
    JAMA ONCOLOGY, 2016, 2 (12) : 1543 - 1544
  • [29] Modulating autoimmunity: pick your PI3 kinase
    Pamela S Ohashi
    James R Woodgett
    Nature Medicine, 2005, 11 : 924 - 925
  • [30] A stabilized demethoxyviridin derivative inhibits PI3 kinase
    Yuan, Hushan
    Pupo, Monica T.
    Blois, Joe
    Smith, Adam
    Weissleder, Ralph
    Clardy, Jon
    Josephson, Lee
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (15) : 4223 - 4227
12345